456R-3

IDH1 R132H (MRQ-67) Rabbit Monoclonal Antibody

• Synonyme(s) : Isocitrate dehydrogenase 1
• Code UNSPSC : 12352203

Propriétés

• Source biologique: rabbit
• Niveau de qualité: 100; 500
• Conjugué: unconjugated
• Forme d'anticorps: culture supernatant
• Type de produit anticorps: primary antibodies
• Clone: MRQ-67, monoclonal
• Description: For In Vitro Diagnostic Use in Select Regions
• Forme: buffered aqueous solution
• Espèces réactives: human
• Conditionnement: vial of 0.1 mL concentrate (456R-34); vial of 0.1 mL concentrate, Research Use Only (456R-34-RUO); vial of 0.5 mL concentrate (456R-35); vial of 1.0 mL concentrate (456R-36); vial of 1.0 mL concentrate, Research Use Only (456R-36-RUO); vial of 1.0 mL pre-dilute ready-to-use (456R-37); vial of 1.0 mL pre-dilute, Research Use Only (456R-37-RUO); vial of 7.0 mL pre-dilute ready-to-use (456R-38); vial of 7.0 mL pre-dilute, ready-to-use, Research Use Only (456R-38-RUO)
• Fabricant/nom de marque: Cell Marque^™
• Technique(s): immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100 (concentrated)
• Isotype: IgG
• Contrôle: acute myeloid leukemia, astrocytoma, glioblastoma, oligodendroglioma
• Conditions d'expédition: wet ice
• Température de stockage: 2-8°C
• Visualisation: cytoplasmic
• Informations sur le gène: human ... IDH1(3417)

Description

Description générale

Isocitrate dehydrogenase 1 (IDH1) functions as an enzyme in the Krebs (citric acid) cycle and is biologically active in the cytoplasmic and peroxisomal compartments under normal conditions. The occurrence of heterozygous missense mutations at an arginine residue at codon 132 (R132) within the coding region for the substrate binding site of IDH1 has been described to promote oncogenesis in several malignancies. Of the identified mutant variants, a histidine substitution (R132H) is one of the more frequently observed point mutations in certain tumor groups of gliomas. Mutations involving IDH1 have been implicated as early events during gliomagenesis and IDH1 mutation status was incorporated into the 2016 WHO Classification of Tumors of the Central Nervous System as a new parameter for sub-classifying diffuse astrocytic and oligodendrogliomal tumors.^3,4 Immunohistochemical identification of IDH1 R132H immunoreactivity can be used as a tool in screening tumors that may be harboring this mutation, such as low grade diffuse and anaplastic astrocytomas, oligodendrogliomas, and secondary glioblastomas.

Qualité

United States - IVD
Canada - RUO
European Union - IVD
Japan - RUO

Forme physique

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide.

Notes préparatoires

Download the IFU specific to your product lot and format
Note: This requires a keycode which can be found on your packaging or product label.

Autres remarques

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Informations légales

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Informations sur la sécurité

• Code de la classe de stockage: 12 - Non Combustible Liquids
• Classe de danger pour l'eau (WGK): WGK 2
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable